Last reviewed · How we verify
FluLaval® Quadrivalent
FluLaval Quadrivalent is an inactivated influenza vaccine that stimulates the immune system to produce antibodies against four strains of influenza virus.
FluLaval Quadrivalent is an inactivated influenza vaccine that stimulates the immune system to produce antibodies against four strains of influenza virus. Used for Seasonal influenza prevention in adults and children (6 months and older).
At a glance
| Generic name | FluLaval® Quadrivalent |
|---|---|
| Also known as | Quadrivalent seasonal influenza vaccine GSK2282512A, GSK2282512A, FLU Q-QIV (GSK2282512A) |
| Sponsor | GlaxoSmithKline |
| Drug class | Inactivated influenza vaccine |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
The vaccine contains inactivated (killed) influenza virus particles representing two influenza A strains and two influenza B strains. When administered, it triggers both humoral and cellular immune responses, leading to the production of protective antibodies and memory immune cells that recognize and neutralize circulating influenza viruses during the flu season.
Approved indications
- Seasonal influenza prevention in adults and children (6 months and older)
Common side effects
- Injection site soreness
- Injection site erythema
- Myalgia
- Headache
- Fatigue
- Low-grade fever
Key clinical trials
- A Study of Modified mRNA Vaccines in Healthy Adults (PHASE1)
- High vs. Standard Dose Influenza Vaccine in Adult SOT Recipients (PHASE2)
- A Study on the Safety and Immunogenicity of Influenza, Respiratory Syncytial Virus, Human Metapneumovirus and Parainfluenza Vaccines in Adults 18 to 49 Years of Age. (PHASE1)
- A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ≥50 Years of Age (PHASE3)
- High vs. Standard Dose Influenza Vaccine in Lung Allograft Recipients (PHASE2)
- A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1010 in Healthy Adults (PHASE2)
- Study to Assess the Immune Response and the Safety Profile of a High-Dose Quadrivalent Influenza Vaccine (QIV-HD) Compared to a Standard-Dose Quadrivalent Influenza Vaccine (QIV-SD) in Taiwanese Adults 65 Years of Age and Older (PHASE3)
- Study to Evaluate the Effectiveness of a High-Dose Quadrivalent Influenza Vaccine (QIV-HD) Compared to a Standard-Dose Quadrivalent Influenza Vaccine (QIV-SD) in Adults 65 Years of Age and Older (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- FluLaval® Quadrivalent CI brief — competitive landscape report
- FluLaval® Quadrivalent updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI